Sun Pharmaceutical Industries (SUNPHARMA) Weekly Analysis
Price & Volume
The stock price moved up by 1.24% during the week ending April 17, 2026. Trading activity saw a total volume of 15,906,704 shares, which is a decrease of 13.64% compared to the previous week. The stock closed at 1675.5, remaining below both its 50-day and 200-day moving averages.
Technicals
The asset concluded the week at 1675.5, reflecting a 1.24% increase. The 50-day moving average, which represents the average price over the last 50 days, is currently at 1695.22 with a downward slope. Momentum indicators show the Relative Strength Index (RSI) at 40.43, indicating moderate momentum, while the MACD histogram remains negative at -7.36. Volatility, measured by the Bollinger Band width, is at 10.29%. The current technical regime is characterized by a downward trend in moving averages and mixed momentum signals, with price trading below the 50-day average.
Fundamentals
Sun Pharmaceutical Industries shows sustained growth, with revenue rising 8.4% YoY and net profit up 14.1% YoY as of March 2025. The company maintains strong profitability, evidenced by a TTM EBITDA margin of 31.6%, representing the percentage of revenue remaining after operating expenses. Operating cash flow reached ₹14,072 in the latest annual period, demonstrating the actual cash generated from core business activities. Returns remain healthy, with ROE at 16.1%, which measures the profit generated for each rupee of shareholder equity. The firm currently trades at 92.1× PE and 16.9× PB, reflecting its market valuation relative to earnings and book value. Overall, the company exhibits consistent operational expansion and stable financial health.
News
During the week ending April 19, 2026, Sun Pharmaceutical Industries Ltd experienced notable market activity and corporate developments. On April 16, 2026, the company's stock price declined alongside broader IT sector movements, while market data indicated that 4,967 contracts were drawn for Rs 1,680 puts. Furthermore, on April 17, 2026, reports emerged regarding potential buyout interest from Sun Pharma in Organon. Earlier in the week, on April 15, 2026, analysis focused on the company's U.S. specialty drugs strategy. These events collectively highlighted shifting investor sentiment and strategic interest surrounding the firm's portfolio and market position throughout the period.
Events
Sun Pharmaceutical Industries Limited has clarified that recent media reports regarding a $12 billion Organon deal are speculative and do not constitute a material event requiring disclosure.
Clarification sought from Sun Pharmaceutical Industries Ltd 10 Apr - Exchange has sought clarification from Sun Pharmaceutical Industries Ltd on April 10, 2026, with reference to news appeared in https://www.moneycontrol.com dated April 10, 2026 quoting …
Sun Pharmaceutical Industries Limited has published newspaper advertisements on 8 April 2026 to inform shareholders about the ongoing postal ballot and e-voting process.
Sun Pharmaceutical Industries Limited is seeking shareholder approval via postal ballot to appoint Ms. Satyavati Berera as an Independent Director for a five-year term. This appointment aims to ensure regulatory compliance and maintain board diversity following the upcoming retirement of the current Independent Director.
Sun Pharmaceutical Industries Limited submitted the Regulation 74(5) compliance certificate for the quarter ended 31 March 2026, confirming that all dematerialization requests were processed within the prescribed timelines.
CRISIL Ratings has reaffirmed Sun Pharmaceutical Industries Limited's 'CRISIL AAA/Stable/CRISIL A1+' ratings, reflecting the company's strong market leadership in domestic formulations and a robust financial risk profile. This stability is supported by a significant cash surplus and growth in its global specialty business, despite ongoing regulatory and competitive pressures.
ICRA has issued a credit rating rationale report for the entity, providing updated assessment details relevant to stakeholders and investors.
Clarification sought from Sun Pharmaceutical Industries Ltd 10 Apr - Exchange has sought clarification from Sun Pharmaceutical Industries Ltd on April 10, 2026, with reference to news appeared in https://www.moneycontrol.com dated April 10, 2026 quoting …
Sun Pharmaceutical Industries Limited has published newspaper advertisements on 8 April 2026 to inform shareholders about the ongoing postal ballot and e-voting process.
Sun Pharmaceutical Industries Limited is seeking shareholder approval via postal ballot to appoint Ms. Satyavati Berera as an Independent Director for a five-year term. This appointment aims to ensure regulatory compliance and maintain board diversity following the upcoming retirement of the current Independent Director.
Sun Pharmaceutical Industries Limited submitted the Regulation 74(5) compliance certificate for the quarter ended 31 March 2026, confirming that all dematerialization requests were processed within the prescribed timelines.
CRISIL Ratings has reaffirmed Sun Pharmaceutical Industries Limited's 'CRISIL AAA/Stable/CRISIL A1+' ratings, reflecting the company's strong market leadership in domestic formulations and a robust financial risk profile. This stability is supported by a significant cash surplus and growth in its global specialty business, despite ongoing regulatory and competitive pressures.
ICRA has issued a credit rating rationale report for the entity, providing updated assessment details relevant to stakeholders and investors.
Weekly Snapshot
Highlights
- The stock price increased by 1.24% over the week, closing at 1675.5.
- The company clarified that recent media reports regarding a potential $12 billion deal are speculative.
- Technical indicators show the Relative Strength Index (RSI, which measures the speed and change of price movements) at 40.43, suggesting moderate momentum.
- The company maintains strong financial health with a TTM EBITDA margin of 31.6%.
- Trading volume for the week reached 15,906,704 shares, representing a 13.64% decrease compared to the previous week.
What This Means
Sun Pharmaceutical Industries experienced a week of price appreciation despite lower trading volumes. While the stock remains below its 50-day and 200-day moving averages, the company continues to demonstrate stable operational performance and strong financial margins. Management addressed market rumors regarding a potential acquisition, confirming that no material event exists. Technical indicators like the MACD (a tool tracking the relationship between two moving averages) remain in a bearish configuration, though the RSI suggests some stabilization in momentum.
Latest Quarter Info
In the quarter ending December 2025, the company demonstrated solid financial momentum, characterized by consistent growth across both top and bottom-line metrics. Revenue increased by approximately 7.2% sequentially and 13.5% year-over-year, reflecting sustained demand. Profitability remains robust, with an operating margin of 32%, indicating effective cost management despite the scale of operations. The net profit growth of 8.2% sequentially and 16.1% year-over-year highlights strong operational leverage, as earnings growth outpaced revenue gains. With a tax rate of 20% and stable depreciation charges, the company maintains a healthy conversion of operating income into net profit. Overall, the financial results suggest a stable trajectory with positive signals from both quarterly and annual performance indicators, underscoring the efficiency of the underlying business model.